Gastric Cancer - Pipeline Review, H2 2017

Date: October 31, 2017
Pages: 1110
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GE94D3AFA18EN
Leaflet:

Download PDF Leaflet

Gastric Cancer - Pipeline Review, H2 2017
Gastric Cancer - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H2 2017, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 2, 14, 72, 87, 6, 84, 14 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 8, 4, 11 and 1 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Gastric Cancer - Overview
Gastric Cancer - Therapeutics Development
Gastric Cancer - Therapeutics Assessment
Gastric Cancer - Companies Involved in Therapeutics Development
Gastric Cancer - Drug Profiles
Gastric Cancer - Dormant Projects 1047
Gastric Cancer - Discontinued Products 1056
Gastric Cancer - Product Development Milestones 1059
Appendix 1079

LIST OF TABLES

Number of Products under Development for Gastric Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Products under Development by Companies, H2 2017 (Contd.11), H2 2017
Products under Development by Companies, H2 2017 (Contd.12), H2 2017
Products under Development by Companies, H2 2017 (Contd.13), H2 2017
Products under Development by Companies, H2 2017 (Contd.14), H2 2017
Products under Development by Companies, H2 2017 (Contd.15), H2 2017
Products under Development by Companies, H2 2017 (Contd.16), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Gastric Cancer - Pipeline by 3SBio Inc, H2 2017
Gastric Cancer - Pipeline by AbbVie Inc, H2 2017
Gastric Cancer - Pipeline by AbGenomics International Inc, H2 2017
Gastric Cancer - Pipeline by Abion Inc, H2 2017
Gastric Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2017
Gastric Cancer - Pipeline by ADC Therapeutics Sarl, H2 2017
Gastric Cancer - Pipeline by Aduro BioTech Inc, H2 2017
Gastric Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
Gastric Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2017
Gastric Cancer - Pipeline by Almac Discovery Ltd, H2 2017
Gastric Cancer - Pipeline by Alteogen Inc, H2 2017
Gastric Cancer - Pipeline by Ambrx Inc, H2 2017
Gastric Cancer - Pipeline by amcure GmbH, H2 2017
Gastric Cancer - Pipeline by Amgen Inc, H2 2017
Gastric Cancer - Pipeline by ANP Technologies Inc, H2 2017
Gastric Cancer - Pipeline by Antikor Biopharma Ltd, H2 2017
Gastric Cancer - Pipeline by arGEN-X BV, H2 2017
Gastric Cancer - Pipeline by Array BioPharma Inc, H2 2017
Gastric Cancer - Pipeline by Asana BioSciences LLC, H2 2017
Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017
Gastric Cancer - Pipeline by Astellas Pharma Inc, H2 2017
Gastric Cancer - Pipeline by AstraZeneca Plc, H2 2017
Gastric Cancer - Pipeline by Athenex Inc, H2 2017
Gastric Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2017
Gastric Cancer - Pipeline by Bayer AG, H2 2017
Gastric Cancer - Pipeline by BeiGene Ltd, H2 2017
Gastric Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2017
Gastric Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2017
Gastric Cancer - Pipeline by Biocon Ltd, H2 2017
Gastric Cancer - Pipeline by Bioleaders Corp, H2 2017
Gastric Cancer - Pipeline by Bionovis SA, H2 2017
Gastric Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Gastric Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017
Gastric Cancer - Pipeline by Camel-IDS NV, H2 2017
Gastric Cancer - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2017
Gastric Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2017
Gastric Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017
Gastric Cancer - Pipeline by Celgene Corp, H2 2017
Gastric Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017
Gastric Cancer - Pipeline by Cellectar Biosciences Inc, H2 2017
Gastric Cancer - Pipeline by Celltrion Inc, H2 2017
Gastric Cancer - Pipeline by Celon Pharma SA, H2 2017
Gastric Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2017
Gastric Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
Gastric Cancer - Pipeline by Curaxys SL, H2 2017
Gastric Cancer - Pipeline by Cytori Therapeutics Inc, H2 2017
Gastric Cancer - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Gastric Cancer - Pipeline by Debiopharm International SA, H2 2017
Gastric Cancer - Pipeline by Deciphera Pharmaceuticals LLC, H2 2017
Gastric Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2017
Gastric Cancer - Pipeline by Eddingpharm Inc, H2 2017
Gastric Cancer - Pipeline by Eli Lilly and Co, H2 2017
Gastric Cancer - Pipeline by EOS Biosciences Inc, H2 2017
Gastric Cancer - Pipeline by Erytech Pharma SA, H2 2017
Gastric Cancer - Pipeline by Esperance Pharmaceuticals Inc, H2 2017
Gastric Cancer - Pipeline by Exelixis Inc, H2 2017
Gastric Cancer - Pipeline by F-star Biotechnology Ltd, H2 2017
Gastric Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Gastric Cancer - Pipeline by Five Prime Therapeutics Inc, H2 2017
Gastric Cancer - Pipeline by Frost Biologic Inc, H2 2017
Gastric Cancer - Pipeline by Galena Biopharma Inc, H2 2017
Gastric Cancer - Pipeline by Genelux Corp, H2 2017
Gastric Cancer - Pipeline by Genentech Inc, H2 2017
Gastric Cancer - Pipeline by Gilead Sciences Inc, H2 2017
Gastric Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017
Gastric Cancer - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017
Gastric Cancer - Pipeline by GlycoNex Inc, H2 2017
Gastric Cancer - Pipeline by Glycotope GmbH, H2 2017
Gastric Cancer - Pipeline by Green Cross Corp, H2 2017
Gastric Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2017
Gastric Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Gastric Cancer - Pipeline by Horizon Pharma Plc, H2 2017
Gastric Cancer - Pipeline by Humanigen Inc, H2 2017
Gastric Cancer - Pipeline by Hummingbird Bioscience Pte Ltd, H2 2017
Gastric Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2017
Gastric Cancer - Pipeline by Ignyta Inc, H2 2017
Gastric Cancer - Pipeline by Ildong Pharmaceutical Co Ltd, H2 2017
Gastric Cancer - Pipeline by Immunomedics Inc, H2 2017
Gastric Cancer - Pipeline by Incyte Corp, H2 2017
Gastric Cancer - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Gastric Cancer - Pipeline by Inspyr Therapeutics Inc, H2 2017
Gastric Cancer - Pipeline by Insys Therapeutics Inc, H2 2017
Gastric Cancer - Pipeline by Ipsen SA, H2 2017
Gastric Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
Gastric Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017
Gastric Cancer - Pipeline by Johnson & Johnson, H2 2017
Gastric Cancer - Pipeline by Jounce Therapeutics Inc, H2 2017
Gastric Cancer - Pipeline by Konruns Pharmaceutical Co Ltd, H2 2017
Gastric Cancer - Pipeline by Kringle Pharma Inc, H2 2017
Gastric Cancer - Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2017
Gastric Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
Gastric Cancer - Pipeline by LATITUDE Pharmaceuticals Inc, H2 2017
Gastric Cancer - Pipeline by LegoChem Biosciences Inc, H2 2017
Gastric Cancer - Pipeline by LinXis BV, H2 2017
Gastric Cancer - Pipeline by MacroGenics Inc, H2 2017
Gastric Cancer - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017
Gastric Cancer - Pipeline by MaxiVAX SA, H2 2017
Gastric Cancer - Pipeline by Mebiopharm Co Ltd, H2 2017
Gastric Cancer - Pipeline by MedImmune LLC, H2 2017
Gastric Cancer - Pipeline by Merck & Co Inc, H2 2017
Gastric Cancer - Pipeline by Merck KGaA, H2 2017
Gastric Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017
Gastric Cancer - Pipeline by Mersana Therapeutics Inc, H2 2017
Gastric Cancer - Pipeline by Merus NV, H2 2017
Gastric Cancer - Pipeline by Mirati Therapeutics Inc, H2 2017
Gastric Cancer - Pipeline by Molecular Partners AG, H2 2017
Gastric Cancer - Pipeline by Molecular Targeting Technologies Inc, H2 2017
Gastric Cancer - Pipeline by Moleculin Biotech Inc, H2 2017
Gastric Cancer - Pipeline by MolMed SpA, H2 2017
Gastric Cancer - Pipeline by NanoCarrier Co Ltd, H2 2017
Gastric Cancer - Pipeline by Novartis AG, H2 2017
Gastric Cancer - Pipeline by Novogen Ltd, H2 2017
Gastric Cancer - Pipeline by OBI Pharma Inc, H2 2017
Gastric Cancer - Pipeline by Oncobiologics Inc, H2 2017
Gastric Cancer - Pipeline by Oncolys BioPharma Inc, H2 2017
Gastric Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H2 2017
Gastric Cancer - Pipeline by OncoResponse Inc, H2 2017
Gastric Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Gastric Cancer - Pipeline by Opsona Therapeutics Ltd, H2 2017
Gastric Cancer - Pipeline by Patrys Ltd, H2 2017
Gastric Cancer - Pipeline by Pfizer Inc, H2 2017
Gastric Cancer - Pipeline by Pharma Mar SA, H2 2017
Gastric Cancer - Pipeline by Pieris Pharmaceuticals Inc, H2 2017
Gastric Cancer - Pipeline by Plexxikon Inc, H2 2017
Gastric Cancer - Pipeline by Prescient Therapeutics Ltd, H2 2017
Gastric Cancer - Pipeline by Puma Biotechnology Inc, H2 2017
Gastric Cancer - Pipeline by Redx Pharma Plc, H2 2017
Gastric Cancer - Pipeline by Rhizen Pharmaceuticals SA, H2 2017
Gastric Cancer - Pipeline by Richter Gedeon Nyrt, H2 2017
Gastric Cancer - Pipeline by Samumed LLC, H2 2017
Gastric Cancer - Pipeline by Sanofi, H2 2017
Gastric Cancer - Pipeline by Selecta Biosciences Inc, H2 2017
Gastric Cancer - Pipeline by Sequella Inc, H2 2017
Gastric Cancer - Pipeline by Shionogi & Co Ltd, H2 2017
Gastric Cancer - Pipeline by Simcere Pharmaceutical Group, H2 2017
Gastric Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2017
Gastric Cancer - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017
Gastric Cancer - Pipeline by Stelic Institute & Co Inc, H2 2017
Gastric Cancer - Pipeline by Supratek Pharma Inc, H2 2017
Gastric Cancer - Pipeline by SynCore Biotechnology Co Ltd, H2 2017
Gastric Cancer - Pipeline by Synovo GmbH, H2 2017
Gastric Cancer - Pipeline by Synthon Holdings BV, H2 2017
Gastric Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017
Gastric Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2017
Gastric Cancer - Pipeline by Takis Srl, H2 2017
Gastric Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2017
Gastric Cancer - Pipeline by Transgene SA, H2 2017
Gastric Cancer - Pipeline by Tyrogenex Inc, H2 2017
Gastric Cancer - Pipeline by United BioPharma Inc, H2 2017
Gastric Cancer - Pipeline by Vaxon Biotech, H2 2017
Gastric Cancer - Pipeline by ViiV Healthcare Ltd, H2 2017
Gastric Cancer - Pipeline by Viracta Therapeutics Inc, H2 2017
Gastric Cancer - Pipeline by XuanZhu Pharma Co Ltd, H2 2017
Gastric Cancer - Pipeline by Zymeworks Inc, H2 2017
Gastric Cancer - Dormant Projects, H2 2017
Gastric Cancer - Dormant Projects, H2 2017 (Contd.1), H2 2017
Gastric Cancer - Dormant Projects, H2 2017 (Contd.2), H2 2017
Gastric Cancer - Dormant Projects, H2 2017 (Contd.3), H2 2017
Gastric Cancer - Dormant Projects, H2 2017 (Contd.4), H2 2017
Gastric Cancer - Dormant Projects, H2 2017 (Contd.5), H2 2017
Gastric Cancer - Dormant Projects, H2 2017 (Contd.6), H2 2017
Gastric Cancer - Dormant Projects, H2 2017 (Contd.7), H2 2017
Gastric Cancer - Dormant Projects, H2 2017 (Contd.8), H2 2017
Gastric Cancer - Discontinued Products, H2 2017
Gastric Cancer - Discontinued Products, H2 2017 (Contd.1), H2 2017
Gastric Cancer - Discontinued Products, H2 2017 (Contd.2), H2 2017

LIST OF FIGURES

Number of Products under Development for Gastric Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

3SBio Inc
AbbVie Inc
AbGenomics International Inc
Abion Inc
Adaptimmune Therapeutics Plc
ADC Therapeutics Sarl
Aduro BioTech Inc
Advenchen Laboratories LLC
Allist Shanghai Pharmaceutical Technology Co Ltd
Almac Discovery Ltd
Alteogen Inc
Ambrx Inc
amcure GmbH
Amgen Inc
ANP Technologies Inc
Antikor Biopharma Ltd
arGEN-X BV
Array BioPharma Inc
Asana BioSciences LLC
Aslan Pharmaceuticals Pte Ltd
Astellas Pharma Inc
AstraZeneca Plc
Athenex Inc
Basilea Pharmaceutica Ltd
Bayer AG
BeiGene Ltd
Beijing Hanmi Pharmaceutical Co Ltd
Betta Pharmaceuticals Co Ltd
Biocon Ltd
Bioleaders Corp
Bionovis SA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Camel-IDS NV
Cancer Prevention Pharmaceuticals Inc
Cascadian Therapeutics Inc
CBT Pharmaceuticals Inc
Celgene Corp
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Celltrion Inc
Celon Pharma SA
Chipscreen Biosciences Ltd
Chugai Pharmaceutical Co Ltd
Curaxys SL
Cytori Therapeutics Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Deciphera Pharmaceuticals LLC
Dr. Reddy's Laboratories Ltd
Eddingpharm Inc
Eli Lilly and Co
EOS Biosciences Inc
Erytech Pharma SA
Esperance Pharmaceuticals Inc
Exelixis Inc
F-star Biotechnology Ltd
F. Hoffmann-La Roche Ltd
Five Prime Therapeutics Inc
Frost Biologic Inc
Galena Biopharma Inc
Genelux Corp
Genentech Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
GlycoNex Inc
Glycotope GmbH
Green Cross Corp
Halozyme Therapeutics Inc
Hanmi Pharmaceuticals Co Ltd
Horizon Pharma Plc
Humanigen Inc
Hummingbird Bioscience Pte Ltd
Hutchison MediPharma Ltd
Ignyta Inc
Ildong Pharmaceutical Co Ltd
Immunomedics Inc
Incyte Corp
Inovio Pharmaceuticals Inc
Inspyr Therapeutics Inc
Insys Therapeutics Inc
Ipsen SA
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Jounce Therapeutics Inc
Konruns Pharmaceutical Co Ltd
Kringle Pharma Inc
Kuhnil Pharmaceutical Co Ltd
Kyowa Hakko Kirin Co Ltd
LATITUDE Pharmaceuticals Inc
LegoChem Biosciences Inc
LinXis BV
MacroGenics Inc
Madrigal Pharmaceuticals Inc.
MaxiVAX SA
Mebiopharm Co Ltd
MedImmune LLC
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Mersana Therapeutics Inc
Merus NV
Mirati Therapeutics Inc
Molecular Partners AG
Molecular Targeting Technologies Inc
Moleculin Biotech Inc
MolMed SpA
NanoCarrier Co Ltd
Novartis AG
Novogen Ltd
OBI Pharma Inc
Oncobiologics Inc
Oncolys BioPharma Inc
OncoMed Pharmaceuticals Inc
OncoResponse Inc
Ono Pharmaceutical Co Ltd
Opsona Therapeutics Ltd
Patrys Ltd
Pfizer Inc
Pharma Mar SA
Pieris Pharmaceuticals Inc
Plexxikon Inc
Prescient Therapeutics Ltd
Puma Biotechnology Inc
Redx Pharma Plc
Rhizen Pharmaceuticals SA
Richter Gedeon Nyrt
Samumed LLC
Sanofi
Selecta Biosciences Inc
Sequella Inc
Shionogi & Co Ltd
Simcere Pharmaceutical Group
Sorrento Therapeutics Inc
Spectrum Pharmaceuticals Inc
Stelic Institute & Co Inc
Supratek Pharma Inc
SynCore Biotechnology Co Ltd
Synovo GmbH
Synthon Holdings BV
Taiho Pharmaceutical Co Ltd
Taiwan Liposome Company Ltd
Takis Srl
Tessa Therapeutics Pte Ltd
Transgene SA
Tyrogenex Inc
United BioPharma Inc
Vaxon Biotech
ViiV Healthcare Ltd
Viracta Therapeutics Inc
XuanZhu Pharma Co Ltd
Zymeworks Inc
Skip to top


Gastric Cancer - Pipeline Review, H1 2017 US$ 2,500.00 May, 2017 · 982 pages
Rectal Cancer - Pipeline Review, H2 2017 US$ 2,000.00 Aug, 2017 · 128 pages
Gastric Ulcers - Pipeline Review, H2 2017 US$ 2,000.00 Sep, 2017 · 45 pages
Ureter Cancer - Pipeline Review, H2 2017 US$ 2,000.00 Oct, 2017 · 144 pages
Rectal Cancer - Pipeline Review, H1 2017 US$ 2,000.00 Mar, 2017 · 130 pages

Ask Your Question

Gastric Cancer - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: